Edaravone Injected at the Start of Reperfusion Suppresses Myonephropathic Metabolic Syndrome in Rats

Abstract

The purpose of this study was to evaluate whether edaravone (Radicut^®, Mitsubishi Tanabe Pharma Co., Osaka, Japan) injected at the start of reperfusion can suppress myonephropathic-metabolic syndrome (MNMS). MNMS models were made by clamping the bilateral common femoral arteries for 5 hours. At de-clamping (at the start of reperfusion), they were intra-peritoneal injected with 9.0 mg/kg of edaravone (the edaravone group, n = 5) or an equal volume of saline (the control group, n = 5). At five hours after de-clamping, the lower extremity muscles were stained with hematoxylin & eosin (H&E) to count the viable cells, and periodic acid- Schiff (PAS) to assess the glycogen storage. The lungs were also stained with H&E to expresse the alveolar wall thickness, and naphthol AS-D chloroacetate esterase to label infiltrating active neutrophils.

The viable muscle cells in the edaravone group was significantly greater than that of the control group (593 ± 60 vs. 258 ± 31 cells/mm², p < 0.01). The PAS-positive area in the edaravone group was also significantly higher than that in the control group (30.1 ± 6.9 vs. 7.3 ± 2.1%, p < 0.001). The alveolar wall thickness in the edaravone group was significantly lower than that in the control group (63.6 ± 5.6 vs. 17.2 ± 5.2%, p < 0.001). The active neutrophil infiltration in the edaravone group was also significantly lower than that in the control group (249 ± 59 vs. 68 ± 8 cells/mm², p < 0.001).

We conclude that edaravone injected at the start of reperfusion can suppress not only muscle reperfusion injury but also lung damage.

Keywords

myonephropathic metabolic syndrome - reperfusion injury - free radical - edaravone (Radicut)

Note

This study was presented at the Arteriosclerosis Thrombosis and Vascular Biology Scientific Sessions, Chicago on April 2012 and Florida on April 2013, and the 55th Annual World Congress of International College of Angiology, New Haven on November 2013.

• References

• 1 Haimovici H. Arterial embolism with acute massive ischemic myopathy and myoglobinuria: evaluation of a hitherto unreported syndrome with report of two cases. Surgery 1960; 47: 739-747
• 2 Watanabe K, Watanabe K, Hayase T. Radical scavenging mechanism of MCI-186. Jpn Pharmacol Ther 1997; 25 (Suppl): S1699-S1707 (Abst in English)
• 3 Yamamura M, Miyamoto Y, Mitsuno M , et al. Suppression of rat lower extremity postoperative reperfusion injury with edaravone. Int J Angiol 2006; 15: 34-36
• 4 Yamamura M, Miyamoto Y, Mitsuno M, Tanaka H, Ryomoto M. Edaravone protects against tissue damage in the lung and kidney induced by myonephropathic metabolic syndrome. Int J Angiol 2010; 19 (1) e38-e40
• 5 Kitanaka Y, Makuuchi H, Murakami H , et al. Effects of edaravone on cerebral protection during aortic arch surgery. [Abstract in English] Jpn J Cardiovasc Surg 2011; 40: 48-53
• 6 Chiba K, Makuuchi H, Murakami H , et al. Effects of edaravone on prevention of paraplegia caused by ischemic spinal cord. [Abstract in English] Jpn J Cardiovasc Surg 2008; 37: 82-90
• 7 Uchida HA, Takatsuka T, Shikata K , et al. Edaravone attenuate angiotensin II-induced abdominal aortic aneurysms in apolipoprotein E-deficient mice. Arteriosclerosis Thrombosis and Vascular Biology 2011 Scientific Sessions . Program Abstr 2011;
• 8 Morimoto K, Hasegawa T, Tanaka A , et al. Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats. J Vasc Surg 2012; 55 (6) 1749-1758
• 9 Yamamura M, Miyamoto Y, Mitsuno M , et al. Edaravone reduces mitochondrial damage due to reperfusion injury following leg ischemia in rats. Int J Angiol 2010; 19 (4) e129-e131
• 10 Watanabe T, Morita I, Nishi H, Murota S. Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 1988; 33 (1) 81-87
• 11 Yamamura M, Miyamoto Y, Mitsuno M , et al. Suppression of postoperative intimal hyperplasia with edaravone in a Rat Model. Int J Angiol 2005; 14: 151-154